The pneumonia therapeutics market will be driven by substantial rise in number of ventilator-associated and community-acquired bacterial pneumonia cases and ongoing clinical trials for the advancement of vaccines and drug molecules. Pneumonia is an infection of the lungs which might infect one or both lungs and fill them up with fluid.

It is caused by fungi, viruses, and bacteria. The disease is considered dangerous for adults, infants, those with weakened immune systems, and people suffering from other diseases as well. The treatment of pneumonia usually is dependent upon the germs that cause it.

Bacterial pneumonia is generally treated with antibiotics. The particular antibiotic choice depends on factors like the general health of an individual, the type of medications one is using, any indication of antibiotic resistance in the local community as well the individuala??s age, and other health conditions that one might have.

Additionally, medications to give relieve from pain and lower fever might also help during treatment. Meanwhile, in the case of fungal pneumonia, antifungal medicines are prescribed by the physicians. Thus, the market is driven by various medications available in the market for the treatment of different types of pneumonia.

Pneumonia therapeutics market is segmented in terms of drug class, age group, infection type, distribution channel, and regional landscape.

Based on drug class, the pneumonia therapeutics market is classified into antifungal drugs, antiviral drugs, and antibacterial drugs. Antibacterial drugs are likely to witness around 8% CAGR over the forthcoming time period owing to the growing cases of bacterial pneumonia and introduction of new therapeutics.

In terms of age group, the overall pneumonia therapeutics market is bifurcated into geriatric, adult, and pediatric. Among these, pediatric segment held a market value of more than $336 million in 2019, owing to high prevalence of pneumonia in elderly population due to their weakened immunity.

With respect to infection type, the pneumonia therapeutics market is classified into ventilator-associated pneumonia (VAP), community-acquired pneumonia (CAP), and hospital-acquired pneumonia (HAP). Hospital-acquired pneumonia will witness around 7.5% CAGR over the projected time period owing to the increasing incidence of HAP in severely ill patients and prolonged hospital stays.

Based on distribution channel, the pneumonia therapeutics market is categorized into online pharmacies, retail pharmacies, and hospital pharmacies. Among these, the online pharmacies segment is likely to represent approximately 16% market share by the end of the analysis period owing to the ease in accessibility and promotional discounts offered by the online pharmacies.

From a regional frame of reference, Europe accounted for a market value of more than $375 million in 2019, attributable to favorable healthcare infrastructure in developed countries and high prevalence of pneumonia therapeutics.